Holen Sie sich die Stockscreener-App
128.97
0.46%
-0.59
Vorhandelsmarkt:
128.92
-0.05
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Illumina Inc Aktie (ILMN) Neueste Nachrichten
ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN - MarketBeat
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term - Nasdaq
DNA Microarray Market is expected to reach US$ 6.12 billion - openPR.com
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ILMN: Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook - TradingView
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - TradingView
ILMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Boosts Stake in Illumina, Inc. $ILMN - MarketBeat
Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus
Illumina, Inc. (ILMN) Stock Analysis: Exploring The Upside With A 33% Return On Equity - DirectorsTalk Interviews
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing - Yahoo Finance
Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating - TipRanks
Andra AP fonden Buys 58,209 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Position Boosted by Citigroup Inc. - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected MultiomicsPR Newswire APAC - PR Newswire Asia
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina
Illumina, Inc. Whole-Genome Sequencing Technology to Accelerate Rare Disease Testing in Florida - marketscreener.com
Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. Unveils Revolutionary Genomic Advancements - Devdiscourse
[PRNewswire] Illumina Launches TruPath Genome - Yonhap News Agency
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally - The Motley Fool
The next generation is shaping the future of rare diseases - Illumina
Evercore ISI reiterates Illumina stock rating on competitive positioning - Investing.com
Evercore ISI reiterates Illumina stock rating on competitive positioning By Investing.com - Investing.com India
Canaccord reiterates Illumina stock Hold rating after Roche pricing By Investing.com - Investing.com Canada
Canaccord reiterates Illumina stock Hold rating after Roche pricing - Investing.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Present - PharmiWeb.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - Yahoo Finance
Illumina partners go beyond the genome, driving cancer breakthroughs - marketscreener.com
How Illumina multiomics helps scientists track elusive ovarian cancers - Stock Titan
Vestmark Advisory Solutions Inc. Sells 22,703 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Bought by North Star Asset Management Inc. - MarketBeat
Illumina Genome Push Raises Questions On Growth, Adoption And Valuation - simplywall.st
Assessing Illumina (ILMN) Valuation After Recent Share Price Rebound And Longer Term Volatility - Yahoo Finance
Illumina (ILMN) Chief Legal Officer sells 1,336 common shares in open market - Stock Titan
Illumina launches TruPath Genome, setting a new standard in genomic insight - Investing News Network
Illumina Launches TruPath Genome Workflow Solution - marketscreener.com
NovaSeq X Series innovation roadmap - Illumina
8,500 Shares in Illumina, Inc. $ILMN Purchased by Monetta Financial Services Inc. - MarketBeat
Next Generation Sequencing Market Competitive Landscape - GlobeNewswire
Illumina, Inc. $ILMN Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Illumina unveils NovaSeq X upgrades with 40% output increase - Investing.com Australia
Illumina, Inc. (ILMN) Stock Analysis: Exploring a 15.62% Potential Upside in the Genomics Sector - DirectorsTalk Interviews
Faster DNA decoding: Illumina’s NovaSeq X gets 40% more data, higher accuracy - Stock Titan
Illumina Beat Q4 Earnings and Closed a $350M Acquisition. Here’s What Investors Need to Know - TIKR.com
Why Illumina Inc. stock is a must watch in 20252025 Support & Resistance & Free Verified High Yield Trade Plans - mfd.ru
Illumina, Inc. $ILMN Shares Sold by Vanguard Group Inc. - MarketBeat
Jupiter Asset Management Ltd. Makes New $16.69 Million Investment in Illumina, Inc. $ILMN - MarketBeat
Scott Davies reports sale of 323 Illumina shares (NASDAQ: ILMN) - Stock Titan
This once-hot cancer-detection company’s stock got cut in half after a failed trial - MarketWatch
Skandinaviska Enskilda Banken AB publ Increases Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina SVP Leckman sells $275k in stock By Investing.com - Investing.com South Africa
Illumina SVP Leckman sells $275k in stock - Investing.com Australia
Is It Time To Reassess Illumina (ILMN) After Recent Share Price Volatility - Yahoo Finance
We Think That There Are Some Issues For Illumina (NASDAQ:ILMN) Beyond Its Promising Earnings - 富途牛牛
Insider Sell: Patricia Leckman Sells Shares of Illumina Inc (ILM - GuruFocus
0.04%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):